- Home
- NMS vs MNOV Comparison
NMS vs MNOV Comparison
Compare NMS & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMS | MNOV |
|---|---|---|
| Founded | 1993 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 76.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | NMS | MNOV |
|---|---|---|
| Price | $11.92 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 12.0K | ★ 103.8K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.21 | $1.13 |
| 52 Week High | $12.18 | $2.24 |
Technical Indicators
Market Signals| Indicator | NMS | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 47.35 | 54.73 |
| Support Level | $11.84 | $1.48 |
| Resistance Level | $12.00 | $1.60 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 45.36 | 57.95 |
Price Performance
Historical ComparisonAbout NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.